Ekso Bionics (EKSO) Fundamental Analysis: Revenue, Earnings & Valuation

0.17 / 10

Underperform

Fundamental analysis rates EKSO as Underperform with a 0.2/10 score. Asset‑MV and Profit‑MV are modestly positive, but Cash‑MV, ROA, profit margins and cash‑flow ratios are negative, indicating weak profitability and liquidity.

Analysis Checks(2/10)

Revenue-MV

Value-2.62

Score1/3

Weight54.44%

1M Return-0.97%

ROA (%)

Value-50.02

Score1/3

Weight44.64%

1M Return-0.82%

Net cash flow from operating activities / Operating revenue (%)

Value-92.20

Score1/3

Weight70.39%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-202.27%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-50.02

Score1/3

Weight44.64%

1M Return-0.82%

EBIT / Total operating revenue (%)

Value-88.96

Score1/3

Weight39.80%

1M Return-0.83%

Asset-MV

Value-0.55

Score3/3

Weight-307.25%

1M Return4.62%

Net profit / Total operating revenue (%)

Value-91.37

Score1/3

Weight45.46%

1M Return-0.84%

Cash-MV

Value0.02

Score1/3

Weight191.74%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight118.42%

1M Return-2.39%

Is EKSO fundamentally strong?

EKSO scores 0.17/10 on fundamentals and holds a Premium valuation at present. Backed by its -107.62% ROE, -91.37% net margin, -2.90 P/E ratio, 3.75 P/B ratio, and 41.76% earnings growth, these metrics solidify its Underperform investment rating.